{"id":16013,"date":"2014-03-13T11:54:44","date_gmt":"2014-03-13T16:54:44","guid":{"rendered":"http:\/\/cmeded.wpengine.com\/?page_id=16013"},"modified":"2023-08-24T18:48:37","modified_gmt":"2023-08-24T23:48:37","slug":"staging","status":"publish","type":"page","link":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/","title":{"rendered":"Estadificaci\u00f3n"},"content":{"rendered":"<h4 class=\"section-title\">Estadificaci\u00f3n<\/h4>\n<p class=\"section-content\">En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda.  Los m\u00e9dicos usan estudios como las pruebas de cambios cromos\u00f3micos o la respuesta del paciente a la terapia para ofrecer un pron\u00f3stico.  Los m\u00e9dicos clasifican la LLA en funci\u00f3n de si no est\u00e1 tratada, si est\u00e1 en remisi\u00f3n o si es recurrente.<\/p>\n<div class=\"clapat-tabs\" id=\"aml\"><div class=\"tabs-bg\"><\/div><ul class=\"staging-tab-menu\"><li><a href=\"#tabs-270\"><br \/>\nNo tratada<\/a><\/li>\n<li><a href=\"#tabs-271\"><br \/>\nEn remisi\u00f3n<\/a><\/li>\n<li><a href=\"#tabs-272\"><br \/>\nRecidivante<\/a><\/li><\/ul><div class=\"list-wrap\"><div id=\"tabs-270\"><\/p>\n<h4 class=\"section-title hidden-title\">No tratada<\/h4>\n<p><div id=\"stage\" style=\"width: 268px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/blast-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/blast-cells-es.jpg\" alt=\"No tratada\" class=\"aligncenter\" style=\"max-width:350px;\"\/><\/a><p id=\"caption-stage\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">La LLA no tratada incluye a todos los pacientes reci\u00e9n diagnosticados que a\u00fan no se sometieron a un tratamiento.  Estos pacientes pueden presentar un hemograma anormal, as\u00ed como signos y s\u00edntomas de LLA.<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div>\n<div id=\"tabs-271\"><\/p>\n<h4 class=\"section-title hidden-title\">En remisi\u00f3n<\/h4>\n<p><div id=\"stage\" style=\"width: 269px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/normal-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/normal-cells-es.jpg\" alt=\"En remisi\u00f3n\" class=\"aligncenter\" style=\"max-width:350px;\"\/><\/a><p id=\"caption-stage\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">Esto incluye a todos los pacientes que han realizado tratamientos y por lo cual el c\u00e1ncer se encuentra en remisi\u00f3n. Para que se considere que el c\u00e1ncer est\u00e1 en remisi\u00f3n, el paciente debe presentar un hemograma normal y ausencia de s\u00edntomas; adem\u00e1s, la m\u00e9dula \u00f3sea del paciente debe tener menos de un 5 % de blastocitos.<\/li>\n<\/ul>\n<ul>\n<li class=\"section-content\">Remisi\u00f3n morfol\u00f3gica: blastos menos del 5%<\/li>\n<\/ul>\n<ul>\n<li class=\"section-content\">Remisi\u00f3n Molecular: Sin enfermedad a nivel molecular<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div>\n<div id=\"tabs-272\"><\/p>\n<h4 class=\"section-title hidden-title\">Recidivante<\/h4>\n<p><div id=\"stage\" style=\"width: 272px\" class=\"wp-caption alignnone\"><a href=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/blast-cells-es.jpg\" title=\"Click Image to Enlarge.\"><img decoding=\"async\" aria-describedby=\"caption-stage\" src=\"\/wp-content\/uploads\/sites\/4\/2015\/07\/blast-cells-es.jpg\" alt=\"Recidivante\" class=\"aligncenter\" style=\"max-width:350px;\"\/><\/a><p id=\"caption-stage\" class=\"wp-caption-text\">Click Image to Enlarge.<\/p><\/div><\/p>\n<h5 class=\"section-title\">Descripci\u00f3n<\/h5>\n<ul>\n<li class=\"section-content\">La LLA recidivante incluye a todos los pacientes en los que el c\u00e1ncer volvi\u00f3 a aparecer despu\u00e9s de la etapa de remisi\u00f3n. Estos pacientes tienen otras perspectivas y requieren tratamientos diferentes de los que se indican para los pacientes reci\u00e9n diagnosticados.<\/li>\n<\/ul>\n<hr class=\"hidden-title\"\/>\n<\/div><\/div><\/div>\n<div class=\"clearboth\"><\/div>\n<div class=\"space\" style=\"clear:both; height:25px;\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las pruebas de cambios cromos\u00f3micos o la respuesta del paciente a la terapia para ofrecer un pron\u00f3stico. Los m\u00e9dicos clasifican la LLA en funci\u00f3n de si no est\u00e1 tratada, si est\u00e1 en remisi\u00f3n o [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":16004,"menu_order":5,"comment_status":"closed","ping_status":"open","template":"template-tumor.php","meta":{"footnotes":""},"tags":[10],"class_list":["post-16013","page","type-page","status-publish","hentry","tag-members-only"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n<\/title>\n<meta name=\"description\" content=\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n\" \/>\n<meta property=\"og:description\" content=\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/\" \/>\n<meta property=\"og:site_name\" content=\"CMedEd\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-24T23:48:37+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/\",\"url\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/\",\"name\":\"CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n\",\"isPartOf\":{\"@id\":\"https:\/\/cmeded.com\/es\/#website\"},\"datePublished\":\"2014-03-13T16:54:44+00:00\",\"dateModified\":\"2023-08-24T23:48:37+00:00\",\"description\":\"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las\",\"breadcrumb\":{\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cmeded.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leucemia\",\"item\":\"https:\/\/cmeded.com\/es\/leukemia\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA)\",\"item\":\"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Estadificaci\u00f3n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cmeded.com\/es\/#website\",\"url\":\"https:\/\/cmeded.com\/es\/\",\"name\":\"CMedEd\",\"description\":\"Recurso principal de informaci\u00f3n sobre el c\u00e1ncer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cmeded.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n","description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/","og_locale":"es_ES","og_type":"article","og_title":"CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n","og_description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las","og_url":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/","og_site_name":"CMedEd","article_modified_time":"2023-08-24T23:48:37+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/","url":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/","name":"CMedEd | Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA) | Estadificaci\u00f3n","isPartOf":{"@id":"https:\/\/cmeded.com\/es\/#website"},"datePublished":"2014-03-13T16:54:44+00:00","dateModified":"2023-08-24T23:48:37+00:00","description":"Estadificaci\u00f3n En la actualidad, no existe un sistema formal de estadificaci\u00f3n para la leucemia linfoc\u00edtica aguda. Los m\u00e9dicos usan estudios como las","breadcrumb":{"@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/staging\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cmeded.com\/es\/"},{"@type":"ListItem","position":2,"name":"Leucemia","item":"https:\/\/cmeded.com\/es\/leukemia\/"},{"@type":"ListItem","position":3,"name":"Informaci\u00f3n para comprender la leucemia linfoc\u00edtica aguda (LLA)","item":"https:\/\/cmeded.com\/es\/leukemia\/understanding-acute-lymphoblastic-leukemia-all\/"},{"@type":"ListItem","position":4,"name":"Estadificaci\u00f3n"}]},{"@type":"WebSite","@id":"https:\/\/cmeded.com\/es\/#website","url":"https:\/\/cmeded.com\/es\/","name":"CMedEd","description":"Recurso principal de informaci\u00f3n sobre el c\u00e1ncer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cmeded.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/comments?post=16013"}],"version-history":[{"count":0,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16013\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/pages\/16004"}],"wp:attachment":[{"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/media?parent=16013"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cmeded.com\/es\/wp-json\/wp\/v2\/tags?post=16013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}